Compounds > fenoxazoline
Page last updated: 2024-12-06

fenoxazoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fenoxazoline is an α1-adrenergic receptor antagonist, structurally related to phenoxybenzamine. It acts as a potent and selective inhibitor of norepinephrine release from sympathetic nerve endings, resulting in vasodilation and a decrease in blood pressure. Fenoxazoline is being investigated for its potential therapeutic applications in the treatment of hypertension, Raynaud's phenomenon, and other conditions characterized by vasoconstriction. Its selectivity for α1-adrenergic receptors, along with its potent vasodilatory effects, make it a promising candidate for these indications. Research efforts are focused on optimizing its pharmacological properties and exploring its safety profile in humans. '

fenoxazoline: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71899
CHEMBL ID14012
CHEBI ID134903
SCHEMBL ID193061
MeSH IDM0120329

Synonyms (34)

Synonym
fenoxazolina [inn-spanish]
fenoxazolina
fenossazolina
fenoxazolinum [inn-latin]
fenoxazolinum
fenoxazoline [inn]
einecs 225-437-6
97jjw1w1r3 ,
unii-97jjw1w1r3
fenossazolina [dcit]
D07372
fenoxazoline (inn)
4846-91-7
fenoxazoline
CHEBI:134903
CHEMBL14012
2-[(2-propan-2-ylphenoxy)methyl]-4,5-dihydro-1h-imidazole
1h-imidazole, 4,5-dihydro-2-[[2-(1-methylethyl)phenoxy]methyl]-
2-((2-isopropylphenoxy)methyl)-4,5-dihydro-1h-imidazole
A827539
FT-0601820
fenoxazoline [mi]
fenoxazoline [who-dd]
FD7204
AKOS022217739
SCHEMBL193061
mfcd00868130
DTXSID30197533
bdbm50473145
fenoxazolin
Q5443567
DB13736
AS-49303
AMY13615
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkylbenzeneA monocyclic arene that is benzene substituted with one or more alkyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID91715Binding affinity for imidazoline receptor I-2 in rabbit kidney homogenate (relative to [3H]-Idazoxan radioligand)2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
3D-QSAR CoMFA study on imidazolinergic I(2) ligands: a significant model through a combined exploration of structural diversity and methodology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's2 (33.33)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.92 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies3 (42.86%)4.05%
Observational0 (0.00%)0.25%
Other3 (42.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
bu 224
BU 224: a selective imidazoline 2-receptor blocker		210quinolines
chlorpyrifos
Chlorpyrifos: An organothiophosphate cholinesterase inhibitor that is used as an insecticide and as an acaricide.. chlorpyrifos : An organic thiophosphate that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.		2.2510chloropyridine;
organic thiophosphate		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
insecticide;
xenobiotic
cirazoline
cirazoline: posseses agonist properties at alpha-adrenoreceptor sites; RN given refers to parent cpd		210aromatic ether
2-phenyl-2-imidazoline
[no description available]		210
chlorpyrifos-methyl
chlorpyrifos-methyl : An organic thiophosphate that is O,O-dimethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.		2.2510chloropyridine;
organic thiophosphate		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
environmental contaminant;
insecticide;
xenobiotic
decamethrin
decamethrin: pyrethroid insecticide; RN given refers to cpd without isomeric designation; structure		2.2510aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organobromine compound		agrochemical;
antifeedant;
calcium channel agonist;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
pyrethroid ester insecticide
idazoxan
Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.		210benzodioxine;
imidazolines		alpha-adrenergic antagonist
2-phenylimidazole
[no description available]		210
2-(2-benzofuranyl)-2-imidazoline
2-(2-benzofuranyl)-2-imidazoline: structure given in first source		210benzofurans
tracizoline
tracizoline: RN given for (R-(R*,R*))-2,3-dihydroxybutanedionate (1:1); ligand for imidazoline receptor; structure in first source		210
2-(2-fluoro-5-methylphenyl)-4,5-dihydro-1h-imidazole
2-(2-fluoro-5-methylphenyl)-4,5-dihydro-1H-imidazole: structure in first source		210
pyrethrins
[no description available]		2.2510
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, High
[description not available]		02.3720
Rhinitis, Allergic, Nonseasonal
[description not available]		01.9610
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		02.3720
Rhinitis, Allergic, Perennial
Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc.		01.9610
Ischemia
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.		02.910
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		07.910
Bilateral Nasal Obstruction
[description not available]		0210
Nasal Obstruction
Any hindrance to the passage of air into and out of the nose. The obstruction may be unilateral or bilateral, and may involve any part of the NASAL CAVITY.		1410